Is the price fair?
What INCY's price assumes
Incyte trades at 18.1× earnings against 32.4× for the median Biotechnology name, cheaper than its own group.
18.1
Trailing P/E · Biotechnology median 32.4 · cheaper than the typical name in its group
- Price / sales
- 3.63
Price / sales · as of 2026-Q1
- Price / book
- 3.46
Price / book · as of 2026-Q1
Details›
- Price / book2026-Q1
- 3.46
- Healthcare median P/E362 names
- 31.5
- Biotechnology median P/E158 names
- 32.4
- Market capitalisation
- $19.6B
| Method | Per share |
|---|---|
| What its own history would imply | not meaningful, 14.7× today against a 34.6× median |
| 52-week range | $78.20 – $129.88 |
| Today | $128.15 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Biotechnology
Ranks #2 of 145 by Smart Score